- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 11th, 2007
Piper Jaffray initiates coverage on Nanosphere (Nasdaq: NSPH) with a Buy rating and a $17 price target.
The firm said Nanosphere's core technology is solid and its recent FDA approval for its Verigene molecular diagnostics instrument will lead to long-term revenue growth.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016